Table 4.
Ongoing Randomized Phase III Trials Of Adjuvant Immunotherapy In Early-Stage And Locally Advanced NSCLC
| Eligible Patients | Intervention | Estimated Enrollment | The Primary Endpoint | ||
|---|---|---|---|---|---|
| ANVIL (NCT02595944) |
Stage IB-IIIA NSCLC | Arm A: Surgery→CT→nivolumab,1 year | N=903 | DFS OS |
[43] |
| Arm B: Surgery→CT→observation | |||||
| IMpower010 (NCT02486718) |
Stage II, IIIA, select IIIB NSCLC | Arm A: Surgery→platinum doublet×4 cycles→atezolizumab × 16 cycles | N=1280 | DFS OS |
[44] |
| Arm B: Surgery→platinum doublet×4 cycles→BSC | |||||
| PEARLS (NCT02504372) |
Stage IB/II-IIIA NSCLC | Arm A: Surgery→±CT→pembrolizumab,1year Arm B: Surgery→±CT→placebo,1year |
N=1080 | DFS | [45] |
| KEYNOTE671(NCT03425643) | Stage IIB-IIIA NSCLC | Arm A: pembrolizumab + platinum doublet×4 cycles→Surgery→pembrolizumab × 13 cycles Arm B: placebo +platinum doublet×4 cycles→Surgery→placebo × 13 cycles |
N=786 | EFS OS |
[42] |
| IFCT-1401 (NCT02273375) |
Completely Resectable NSCLC | Arm A: Surgery→±CT→MEDI4736,1year Arm B: Surgery→±CT→placebo,1year |
N=1360 | DFS | [46] |
Abbreviations: NSCLC, non-small-cell lung cancer; NCT, National Clinical Trials; CT, chemotherapy; DFS, Disease-free Survival; OS, Overall Survival; EFS, Event Free Survival; BSC, Best supportive care.